ABOS vs BCAX
ABOS: Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients, with Phase 2 results expected in late 2026. BCAX: Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment outcomes in solid tumors.
Side-by-side fundamentals
| Metric | ABOS | BCAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.21 | $27.96 | |
| Market cap as of 2026-07-23 | $160M | $1.9B | |
| PEG as of 2026-07-23 | n/a | -0.16 | |
| Net margin as of 2026-07-23 | -509.7% | n/a | |
| Operating margin as of 2026-07-23 | -550.0% | n/a | |
| ROE as of 2026-07-23 | -123.1% | -35.9% | BCAX higher |
| ROA as of 2026-07-23 | -79.4% | -33.8% | BCAX higher |
| Debt / equity as of 2026-07-23 | 0.35 | 0.00 | BCAX lower |
| Beta as of 2026-07-23 | 0.32 | 1.01 | |
| 1-year return as of 2026-07-22 close | +43.9% | +150.4% | BCAX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.